Results 31 to 40 of about 14,435 (170)

Nirmatrelvir Plus Ritonavir: First Approval

, 2022
DeclarationsFunding The preparation of this review was not supported by any external funding.Authorship and Conflict of interest During the peer review process the manufacturer of the agent under review was offered an opportunity to comment on the ...
Yvette Lamb (6930427)
core   +1 more source

Nirmatrelvir/ritonavir and risk of long COVID symptoms: a retrospective cohort study

Scientific Reports, 2023
We conducted a retrospective cohort study to assess whether treatment with nirmatrelvir/ritonavir was associated with a reduced risk of long COVID. We enrolled 500 adults with confirmed SARS-CoV-2 who were eligible for nirmatrelvir/ritonavir; 250 who ...
Seth Congdon, Zev Narrowe, Nang Yone, Jacob Gunn, Yuting Deng, Priya Nori, Kelsie Cowman, Marjan Islam, Sharon Rikin, Joanna Starrels   +9 more
doaj   +1 more source

Nirmatrelvir/ritonavir use in pregnant women with SARS-CoV-2 Omicron infection: a target trial emulation [PDF]

, 2023
To date, there is a lack of randomized trial data examining the use of the antiviral nirmatrelvir/ritonavir in severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)-infected pregnant persons. This target trial emulation study aimed to address this
BJ Cowling (15834218), CKH Wong (16544469), KTK Lau (16544472), Y Daoud (17661372), EHY Lau (16543686), MSH Chung (16544478), KW Cheung (17661369), GM Leung (15834224), ICH Au (16544475)   +8 more
core   +2 more sources

A case report of a prolonged decrease in tacrolimus clearance due to co-administration of nirmatrelvir/ritonavir in a lung transplant recipient receiving itraconazole prophylaxis

Journal of Pharmaceutical Health Care and Sciences, 2023
Background Drug-drug interaction management is complex. Nirmatrelvir/ritonavir is a potent cytochrome P450 (CYP) 3A inhibitor and influences pharmacokinetics of co-administered drugs.
Ayumi Tsuzawa, Yoshiki Katada, Keisuke Umemura, Mitsuhiro Sugimoto, Asami Nishikawa, Yu-ki Sato, Yuko Yoshida, Noriaki Kitada, Atsushi Yonezawa, Daisuke Nakajima, Hiroshi Date, Tomohiro Terada   +11 more
doaj   +1 more source

Nirmatrelvir–Ritonavir (Paxlovid) for Mild Coronavirus Disease 2019 (COVID-19) in Pregnancy and Lactation [PDF]

, 2023
Nirmatrelvir-ritonavir (Paxlovid) is recommended to reduce the risk of hospitalization from coronavirus disease 2019 (COVID-19) in pregnancy. Data on use in pregnancy, including prescribing patterns and patient experience (adverse effects, incidence of ...
Prahl, Mary, Yarden Golan, Li, Lin, Golan, Yarden, Lin Li, Lin, Christine, Cassidy, Arianna, Arianna G. Cassidy, Mary K. Prahl, Gaw, Stephanie, Stephanie L. Gaw, Christine Y. Lin   +11 more
core   +1 more source

VV116 or Nirmatrelvir–Ritonavir for Oral Treatment of Covid-19 [PDF]

, 2023
To the Editor: Cao and colleagues (Feb. 2 issue)1 report that the oral antiviral agent VV116 was noninferior to nirmatrelvir–ritonavir in alleviating Covid-19–related ...
Lin, Dan-Yu, Fleming, Thomas R
core   +1 more source

Nirmatrelvir combined with ritonavir for preventing and treating COVID‐19 [PDF]

, 2022
BACKGROUND: Oral nirmatrelvir/ritonavir (Paxlovid®) aims to avoid severe COVID‐19 in asymptomatic people or those with mild symptoms, thereby decreasing hospitalization and death. Due to its novelty, there are currently few published study results.
Kranke, Peter, Meybohm, Patrick, Peter Kranke, Maria Popp, Metzendorf, Maria Inti, Rebecca Kuehn, Weibel, Stephanie, Reis, Stefanie, Kuehn, Rebecca, Stefanie Reis, Patrick Meybohm, Skoetz, Nicole, Ildiko Gagyor, Gagyor, Ildiko, Stephanie Weibel, Nicole Skoetz, Metzendorf, Maria-Inti, Maria-Inti Metzendorf, Popp, Maria   +18 more
core   +1 more source

Optimizing the use of nirmatrelvir/ritonavir in solid organ transplant recipients with COVID-19: A review of immunosuppressant adjustment strategies

Frontiers in Immunology, 2023
The coronavirus disease 2019 (COVID-19) pandemic has caused a significant burden of morbidity and mortality worldwide, with solid organ transplant recipients (SOTRs) being particularly vulnerable.
Yangming Tang, Yue Li, Turun Song
doaj   +1 more source

The interaction between nirmatrelvir/ritonavir and sirolimus: a case report of a kidney recipient with renal insufficiency and COVID-19

Journal of International Medical Research
Nirmatrelvir/ritonavir is a novel drug combination authorized by the US Food and Drug Administration for the treatment of coronavirus disease 2019 (COVID-19).
Yinhua Gong, Dan Shen, Jinfang Shi, Ye Jiang, Jie Gao   +4 more
doaj   +1 more source

Differences in SARS‐CoV‐2 Antigen Persistence in Individuals With Systemic Autoimmune Rheumatic Diseases Compared to the General Population: A RECOVER‐Adult Cohort Study

Arthritis &Rheumatology, EarlyView.
Objective Individuals with systemic autoimmune rheumatic diseases (SARDs) are at risk for worse acute and post–acute COVID‐19 outcomes, though whether individuals with SARDs have longer persistence of viral antigens after COVID‐19 has not been studied.
Naomi J. Patel, Zoe Swank, Jiaqi Wang, Xiaosong Wang, Lauren A. O'Keeffe, Madison Negron, Liya S. Getachew, Louise L. Hansen, Grace Qian, Alene A. Saavedra, Kevin T. Mueller, Natalie A. Davis, Kathleen M. M. Vanni, Sandria Savage, Julie S. Lam, Zachary S. Wallace, David R. Walt, Jeffrey A. Sparks, on behalf of RECOVER‐Adult   +18 more
wiley   +1 more source